Indeed, we were able to demonstrate the following in response to ibrutinib: (1) overall, HD-B cells exhibit an unaltered mechanical phenotype; (2) after exposure to drugs, leukemic cells recover the physiological range of cortical stiffness of HD-Bs; and (3) CLL cells show a partial recovery of actin and myosin colocalization and activation of the actomyosin complex. The gene discussed is MYH14; the disease is B-cell chronic lymphocytic leukemia.